N-alpha-acetyltransferase 10, NatA catalytic subunitGenealiases: ARD1 · ARD1A · ARD1P · DXS707 · LZMS · MAA
Q-omics provides the consensus-scored NAA10 profile across patient tissues and cancer cell-line models. NAA10 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NAA10 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, NAA10 protein abundance shows 25,299 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where NAA10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAA10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAA10 survival associations across molecular data types. NAA10 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAA10 RNA expression–survival associations across cancer types. High NAA10 expression shows unfavorable associations in KIRC, UVM, ACC, ESCA, UCS and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NAA10 RNA expression.
This table summarizes NAA10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAA10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAA10 shows higher tumor expression in HNSC, COAD, BLCA, LIHC, STAD and LUAD. The HNSC box plot shows higher NAA10 RNA expression in tumor versus normal tissue (log2 FC = +0.970, t-test p < 0.001).
This table shows molecular features associated with NAA10 in patient tissues and cancer cell lines. In patient samples, NAA10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NAA10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
